Development of a multigram synthesis of the bradykinin receptor 2 agonist FR-190997 and analogs thereof

Using Fujisawa's B2R agonist FR-190997, we recently demonstrated for the first time that agonism at the Bradykinin Receptor type 2 (B2R) produces substantial antiproliferative effects. FR-190997 elicited an EC₅₀ of 80 nM in the triple-negative breast Cancer cell line MDA-MB-231, a much superior performance to that exhibited by most approved breast Cancer drugs. Consequently, we initiated a program aiming primarily at synthesizing adequate quantities of FR-190997 to support further in vitro and in vivo studies toward its repurposing for various cancers and, in parallel, enable the generation of novel FR-190997 analogs for an SAR study. Prerequisite for this endeavor was to address the synthetic challenges associated with the FR-190997 scaffold, which the Fujisawa chemists had constructed in 20 steps, 13 of which required chromatographic purification. We succeeded in developing a 17-step synthesis amenable to late-stage diversification that eliminated all chromatography and enabled access to multigram quantities of FR-190997 and novel derivatives thereof, supporting further Anticancer research based on B2R agonists.

B2R agonists; FR-190997; cancer; late-stage diversification; quinolines.